News Agency
Men's Weekly

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

  • Written by Media Outreach
HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological...

Read more: AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth...

Understanding Your Rights Around Property After Separation

Property division is one of the most significant financial matters that arises when a relationship ends, and it's also one of the most commonly misunderstood. Many people assume that assets are simply divided equally, but the reality under Australian family... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion